Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

EASE-3. A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of empagliflozin as adjunctive to insulin over 52 weeks in patients with type 1 diabetes mellitus

Project: Types of projectsProject

View graph of relations

ID: 44814789